# Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema.

- **DOI:** [10.57264/cer-2024-0237](https://doi.org/10.57264/cer-2024-0237)
- **Rating:** Sound (3.4 out of 5)
- **Verdict:** A useful population-adjusted comparison fills a practical HAE evidence gap, but residual cross-trial heterogeneity limits confidence in comparative superiority.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.57264%2Fcer-2024-0237

## Key claims

1. Compared with lanadelumab 300 Q4W, garadacimab 200 QM showed statistically significant improvements in all outcomes assessed.
   - Support: Supported
   - Type: Primary finding
   - Basis: consistent reported Q4W estimates from a residual-confounding-prone indirect comparison
   - Location: Abstract; Conclusion; Summary Points
2. Compared with lanadelumab 300 Q2W, garadacimab 200 QM statistically significantly reduced number of moderate and/or severe HAE attacks and improved AE-QoL score.
   - Support: Supported
   - Type: Secondary
   - Basis: two significant estimates accurately reported from a small, population-adjusted indirect comparison
   - Location: Abstract; Results; Conclusion
3. Overall, these results suggest that garadacimab may provide improved therapeutic benefit compared with lanadelumab.
   - Support: Tentative
   - Type: Secondary
   - Basis: broad benefit framing rests on indirect evidence and mixed Q2W statistical results
   - Location: Conclusion
4. The attack rate for patients receiving garadacimab 200 QM was lower than that of patients receiving lanadelumab 300 Q2W (RR: 0.55; 95% CI: 0.22, 1.37; p = 0.200), but this result was not statistically significant.
   - Support: Supported
   - Type: Secondary
   - Basis: the primary Q2W estimate is directly reported but imprecise within an indirect comparison
   - Location: Results, Time-normalized Number of HAE Attacks; Table 5

## Strengths

- **Fills a specific comparative evidence gap** The study provides the first cited population-adjusted comparison of garadacimab with lanadelumab where no head-to-head randomized trial is available, including a comparative QoL analysis.
  - Dimension: contribution
  - Location: Introduction; Discussion, paragraphs 1 and 6
- **Transparent population adjustment and uncertainty reporting** The methods specify anchored and unanchored analyses, balance diagnostics, robust variance estimation, and sequential TEM scenarios. Tables 2–8 report the resulting ESS reductions rather than concealing information loss.
  - Dimension: methodological rigour
  - Location: Statistical Analysis; Scenario Analyses; Tables 2–8
- **Limitations connected to interpretation** The Discussion identifies unresolved eligibility differences, unavailable anxiety and depression covariates, loading-dose differences, and stronger assumptions for the unanchored endpoint, then warns that these differences condition uncertainty.
  - Dimension: positioning
  - Location: Discussion, loading-dose and limitations paragraphs

## Limitations

- **Residual heterogeneity limits comparative inference** The pooled trials differ in phase, duration, eligibility, geography, sponsors, and loading schedules, while important covariates reported as highly ranked could not be adjusted. These differences leave untestable residual confounding.
  - Dimension: methodological rigour
  - Location: Discussion, limitations
- **Weighting sharply reduces effective samples** The QoL analyses lose 49% and 55% of effective sample size after adjustment, leaving imprecise estimates with wide confidence intervals. Other anchored analyses also show material ESS reductions.
  - Dimension: methodological rigour
  - Location: Tables 2, 4, 6, and 8; Table 5
- **Abstract overstates the Q2W pattern** The Abstract reports the two significant Q2W findings but omits that overall attack rate, attacks requiring on-demand treatment, and attack-free status were not statistically significant. The conclusion then describes improved efficacy and QoL broadly across regimens.
  - Dimension: reporting
  - Location: Abstract, Results; Table 5; Conclusion

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The numerical findings are reported consistently, but the HELP trial identifier is inconsistent within the article. The discrepancy appears traceability-related rather than consequential to the reported estimates.
- **Research conduct:** Clean. No supplied-text evidence indicates a research-conduct problem. Statements not visible in the supplied article, including ethics and conflict-of-interest declarations for the secondary analysis, remain assessability gaps rather than reliability findings.
- **Reference integrity:** Clean. 20 of 20 checkable references verified
  - 33 references in manuscript
  - 13 are books, websites or datasets — counted, but not index-checkable
  - citation details diverge from the cited records for 1 reference
  - Citation details diverge for 1 reference:
    - #24 Signorovitch JE , Wu EQ , Yu AP Comparative effectiveness without head-to-head trials . Pharmacoeconomics 28 ( 10 ), 935 – 945 ( 2010 ). 20831302 10.2165/11538370-000000000-00000 (Differs from the cited DOI’s record on: title, authors)
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17